Loading…

A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model

Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single su...

Full description

Saved in:
Bibliographic Details
Published in:Balkan journal of medical genetics 2014-12, Vol.17 (2), p.73-80
Main Authors: Soysal, D., Kızıldağ, S., Saatlı, B., Posacı, C., Soysal, S., Koyuncuoğlu, M., Doğan, Ö. E.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3
cites
container_end_page 80
container_issue 2
container_start_page 73
container_title Balkan journal of medical genetics
container_volume 17
creator Soysal, D.
Kızıldağ, S.
Saatlı, B.
Posacı, C.
Soysal, S.
Koyuncuoğlu, M.
Doğan, Ö. E.
description Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.
doi_str_mv 10.2478/bjmg-2014-0077
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b49f210a36284fc8afb4c606c363edf1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b49f210a36284fc8afb4c606c363edf1</doaj_id><sourcerecordid>1678748188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3</originalsourceid><addsrcrecordid>eNp1kUFv1DAQRiMEoqVw5Yhy5JLisZ3YKySkpSqwUgEJwYmD5djjrFdJvNjOovLrSbqlag8cLI9mPr-x9IriJZBzyoV80-6GrqIEeEWIEI-KU2AAFYGGPL5XnxTPUtoR0jAB4mlxQusVE5LAafFzXX4JB-zL9dj50OGIyadyM25963OI5Xs8aOP_TINu566dDKZyvQ_7HJacH8u8xfKbzuXlaMOAOfqbwedgsX9ePHG6T_ji9j4rfny4_H7xqbr6-nFzsb6qTE1kroyEBg21UBtNKK9XshYooUYuHFsJSjh3GogArRnOhztBzMoyRKTOEsvOis2Ra4PeqX30g47XKmivbhohdkrH7E2PquUrR4Fo1lDJnZHatdw0pDGsYWgdzKx3R9Z-age0Bsccdf8A-nAy-q3qwkFxDozzega8vgXE8GvClNXgk8G-1yOGKSlohBRcgpRz9PwYNTGkFNHdrQGiFrtqsasWu2qxOz94df9zd_F_OufA22Pgt-4zRotdnK7nQu3CFMfZwX_IIKhg7C8SKbWn</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1678748188</pqid></control><display><type>article</type><title>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</title><source>PubMed Central Free</source><source>Publicly Available Content (ProQuest)</source><creator>Soysal, D. ; Kızıldağ, S. ; Saatlı, B. ; Posacı, C. ; Soysal, S. ; Koyuncuoğlu, M. ; Doğan, Ö. E.</creator><creatorcontrib>Soysal, D. ; Kızıldağ, S. ; Saatlı, B. ; Posacı, C. ; Soysal, S. ; Koyuncuoğlu, M. ; Doğan, Ö. E.</creatorcontrib><description>Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.</description><identifier>ISSN: 1311-0160</identifier><identifier>EISSN: 1311-0160</identifier><identifier>DOI: 10.2478/bjmg-2014-0077</identifier><identifier>PMID: 25937801</identifier><language>eng</language><publisher>Poland: De Gruyter Open</publisher><subject>Angiogenesis ; Apoptosis ; Bevacizumab ; Endometriosis ; Original</subject><ispartof>Balkan journal of medical genetics, 2014-12, Vol.17 (2), p.73-80</ispartof><rights>Macedonian Academy of Sciences and Arts 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413445/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413445/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25937801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soysal, D.</creatorcontrib><creatorcontrib>Kızıldağ, S.</creatorcontrib><creatorcontrib>Saatlı, B.</creatorcontrib><creatorcontrib>Posacı, C.</creatorcontrib><creatorcontrib>Soysal, S.</creatorcontrib><creatorcontrib>Koyuncuoğlu, M.</creatorcontrib><creatorcontrib>Doğan, Ö. E.</creatorcontrib><title>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</title><title>Balkan journal of medical genetics</title><addtitle>Balkan J Med Genet</addtitle><description>Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.</description><subject>Angiogenesis</subject><subject>Apoptosis</subject><subject>Bevacizumab</subject><subject>Endometriosis</subject><subject>Original</subject><issn>1311-0160</issn><issn>1311-0160</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kUFv1DAQRiMEoqVw5Yhy5JLisZ3YKySkpSqwUgEJwYmD5djjrFdJvNjOovLrSbqlag8cLI9mPr-x9IriJZBzyoV80-6GrqIEeEWIEI-KU2AAFYGGPL5XnxTPUtoR0jAB4mlxQusVE5LAafFzXX4JB-zL9dj50OGIyadyM25963OI5Xs8aOP_TINu566dDKZyvQ_7HJacH8u8xfKbzuXlaMOAOfqbwedgsX9ePHG6T_ji9j4rfny4_H7xqbr6-nFzsb6qTE1kroyEBg21UBtNKK9XshYooUYuHFsJSjh3GogArRnOhztBzMoyRKTOEsvOis2Ra4PeqX30g47XKmivbhohdkrH7E2PquUrR4Fo1lDJnZHatdw0pDGsYWgdzKx3R9Z-age0Bsccdf8A-nAy-q3qwkFxDozzega8vgXE8GvClNXgk8G-1yOGKSlohBRcgpRz9PwYNTGkFNHdrQGiFrtqsasWu2qxOz94df9zd_F_OufA22Pgt-4zRotdnK7nQu3CFMfZwX_IIKhg7C8SKbWn</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Soysal, D.</creator><creator>Kızıldağ, S.</creator><creator>Saatlı, B.</creator><creator>Posacı, C.</creator><creator>Soysal, S.</creator><creator>Koyuncuoğlu, M.</creator><creator>Doğan, Ö. E.</creator><general>De Gruyter Open</general><general>Macedonian Science of Sciences and Arts</general><general>Sciendo</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20141201</creationdate><title>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</title><author>Soysal, D. ; Kızıldağ, S. ; Saatlı, B. ; Posacı, C. ; Soysal, S. ; Koyuncuoğlu, M. ; Doğan, Ö. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Angiogenesis</topic><topic>Apoptosis</topic><topic>Bevacizumab</topic><topic>Endometriosis</topic><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soysal, D.</creatorcontrib><creatorcontrib>Kızıldağ, S.</creatorcontrib><creatorcontrib>Saatlı, B.</creatorcontrib><creatorcontrib>Posacı, C.</creatorcontrib><creatorcontrib>Soysal, S.</creatorcontrib><creatorcontrib>Koyuncuoğlu, M.</creatorcontrib><creatorcontrib>Doğan, Ö. E.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Balkan journal of medical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soysal, D.</au><au>Kızıldağ, S.</au><au>Saatlı, B.</au><au>Posacı, C.</au><au>Soysal, S.</au><au>Koyuncuoğlu, M.</au><au>Doğan, Ö. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model</atitle><jtitle>Balkan journal of medical genetics</jtitle><addtitle>Balkan J Med Genet</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>17</volume><issue>2</issue><spage>73</spage><epage>80</epage><pages>73-80</pages><issn>1311-0160</issn><eissn>1311-0160</eissn><abstract>Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.</abstract><cop>Poland</cop><pub>De Gruyter Open</pub><pmid>25937801</pmid><doi>10.2478/bjmg-2014-0077</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1311-0160
ispartof Balkan journal of medical genetics, 2014-12, Vol.17 (2), p.73-80
issn 1311-0160
1311-0160
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b49f210a36284fc8afb4c606c363edf1
source PubMed Central Free; Publicly Available Content (ProQuest)
subjects Angiogenesis
Apoptosis
Bevacizumab
Endometriosis
Original
title A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A24%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Angiogenesis%20Inhibitor%20Bevacizumab%20Induces%20Apoptosis%20in%20the%20Rat%20Endometriosis%20Model&rft.jtitle=Balkan%20journal%20of%20medical%20genetics&rft.au=Soysal,%20D.&rft.date=2014-12-01&rft.volume=17&rft.issue=2&rft.spage=73&rft.epage=80&rft.pages=73-80&rft.issn=1311-0160&rft.eissn=1311-0160&rft_id=info:doi/10.2478/bjmg-2014-0077&rft_dat=%3Cproquest_doaj_%3E1678748188%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c508t-c816ec2d15ca02459857e815e47f3972044fa1071aa3eaa34f70c9d3eee2fd0d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1678748188&rft_id=info:pmid/25937801&rfr_iscdi=true